{"pmid":32437749,"title":"Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2.","text":["Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2.","Gastroenterology","Wang, Cheng","Wang, Shaobo","Li, Daixi","Wei, Dong-Qing","Zhao, Jinghong","Wang, Junping","32437749"],"journal":"Gastroenterology","authors":["Wang, Cheng","Wang, Shaobo","Li, Daixi","Wei, Dong-Qing","Zhao, Jinghong","Wang, Junping"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32437749","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1053/j.gastro.2020.05.015","topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393802084353,"score":9.490897,"similar":[{"pmid":32333836,"pmcid":"PMC7181998","title":"Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.","text":["Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2.","We have previously provided the first genetic evidence that angiotensin converting enzyme 2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), and ACE2 protects the lung from injury, providing a molecular explanation for the severe lung failure and death due to SARS-CoV infections. ACE2 has now also been identified as a key receptor for SARS-CoV-2 infections, and it has been proposed that inhibiting this interaction might be used in treating patients with COVID-19. However, it is not known whether human recombinant soluble ACE2 (hrsACE2) blocks growth of SARS-CoV-2. Here, we show that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000-5,000. An equivalent mouse rsACE2 had no effect. We also show that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE2. These data demonstrate that hrsACE2 can significantly block early stages of SARS-CoV-2 infections.","Cell","Monteil, Vanessa","Kwon, Hyesoo","Prado, Patricia","Hagelkruys, Astrid","Wimmer, Reiner A","Stahl, Martin","Leopoldi, Alexandra","Garreta, Elena","Hurtado Del Pozo, Carmen","Prosper, Felipe","Romero, Juan Pablo","Wirnsberger, Gerald","Zhang, Haibo","Slutsky, Arthur S","Conder, Ryan","Montserrat, Nuria","Mirazimi, Ali","Penninger, Josef M","32333836"],"abstract":["We have previously provided the first genetic evidence that angiotensin converting enzyme 2 (ACE2) is the critical receptor for severe acute respiratory syndrome coronavirus (SARS-CoV), and ACE2 protects the lung from injury, providing a molecular explanation for the severe lung failure and death due to SARS-CoV infections. ACE2 has now also been identified as a key receptor for SARS-CoV-2 infections, and it has been proposed that inhibiting this interaction might be used in treating patients with COVID-19. However, it is not known whether human recombinant soluble ACE2 (hrsACE2) blocks growth of SARS-CoV-2. Here, we show that clinical grade hrsACE2 reduced SARS-CoV-2 recovery from Vero cells by a factor of 1,000-5,000. An equivalent mouse rsACE2 had no effect. We also show that SARS-CoV-2 can directly infect engineered human blood vessel organoids and human kidney organoids, which can be inhibited by hrsACE2. These data demonstrate that hrsACE2 can significantly block early stages of SARS-CoV-2 infections."],"journal":"Cell","authors":["Monteil, Vanessa","Kwon, Hyesoo","Prado, Patricia","Hagelkruys, Astrid","Wimmer, Reiner A","Stahl, Martin","Leopoldi, Alexandra","Garreta, Elena","Hurtado Del Pozo, Carmen","Prosper, Felipe","Romero, Juan Pablo","Wirnsberger, Gerald","Zhang, Haibo","Slutsky, Arthur S","Conder, Ryan","Montserrat, Nuria","Mirazimi, Ali","Penninger, Josef M"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32333836","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.cell.2020.04.004","keywords":["covid-19","angiotensin converting enzyme 2","blood vessels","human organoids","kidney","severe acute respiratory syndrome coronavirus","spike glycoproteins","treatment"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493942759426,"score":54.769936},{"pmid":32374032,"title":"Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors.","text":["Letter: intestinal inflammation, COVID-19 and gastrointestinal ACE2 - exploring RAS inhibitors.","We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2].","Aliment Pharmacol Ther","Garg, Mayur","Royce, Simon G","Lubel, John S","32374032"],"abstract":["We read with interest the article by Taxonera et al outlining a high incidence of diarrhoea in patients with inflammatory bowel disease (IBD) diagnosed with coronavirus disease 19 (COVID-19).[1] The relationship between these symptoms and faecal calprotectin would be interesting to note. In patients without IBD and COVID-19, faecal calprotectin was noted to be higher in patients with continuing than resolved diarrhoea, suggesting intestinal inflammation due to COVID-19.[2]."],"journal":"Aliment Pharmacol Ther","authors":["Garg, Mayur","Royce, Simon G","Lubel, John S"],"date":"2020-05-07T11:00:00Z","year":2020,"_id":"32374032","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1111/apt.15814","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138496348192769,"score":52.189945},{"pmid":32405028,"title":"Infection of bat and human intestinal organoids by SARS-CoV-2.","text":["Infection of bat and human intestinal organoids by SARS-CoV-2.","A novel coronavirus-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-emerged in humans in Wuhan, China, in December 2019 and has since disseminated globally(1,2). As of April 16, 2020, the confirmed case count of coronavirus disease 2019 (COVID-19) had surpassed 2 million. Based on full-genome sequence analysis, SARS-CoV-2 shows high homology to SARS-related coronaviruses identified in horseshoe bats(1,2). Here we show the establishment and characterization of expandable intestinal organoids derived from horseshoe bats of the Rhinolophus sinicus species that can recapitulate bat intestinal epithelium. These bat enteroids are fully susceptible to SARS-CoV-2 infection and sustain robust viral replication. Development of gastrointestinal symptoms in some patients with COVID-19 and detection of viral RNA in fecal specimens suggest that SARS-CoV-2 might cause enteric, in addition to respiratory, infection(3,4). Here we demonstrate active replication of SARS-CoV-2 in human intestinal organoids and isolation of infectious virus from the stool specimen of a patient with diarrheal COVID-19. Collectively, we established the first expandable organoid culture system of bat intestinal epithelium and present evidence that SARS-CoV-2 can infect bat intestinal cells. The robust SARS-CoV-2 replication in human intestinal organoids suggests that the human intestinal tract might be a transmission route of SARS-CoV-2.","Nat Med","Zhou, Jie","Li, Cun","Liu, Xiaojuan","Chiu, Man Chun","Zhao, Xiaoyu","Wang, Dong","Wei, Yuxuan","Lee, Andrew","Zhang, Anna Jinxia","Chu, Hin","Cai, Jian-Piao","Yip, Cyril Chik-Yan","Chan, Ivy Hau-Yee","Wong, Kenneth Kak-Yuen","Tsang, Owen Tak-Yin","Chan, Kwok-Hung","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chen, Honglin","Yuen, Kwok Yung","32405028"],"abstract":["A novel coronavirus-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-emerged in humans in Wuhan, China, in December 2019 and has since disseminated globally(1,2). As of April 16, 2020, the confirmed case count of coronavirus disease 2019 (COVID-19) had surpassed 2 million. Based on full-genome sequence analysis, SARS-CoV-2 shows high homology to SARS-related coronaviruses identified in horseshoe bats(1,2). Here we show the establishment and characterization of expandable intestinal organoids derived from horseshoe bats of the Rhinolophus sinicus species that can recapitulate bat intestinal epithelium. These bat enteroids are fully susceptible to SARS-CoV-2 infection and sustain robust viral replication. Development of gastrointestinal symptoms in some patients with COVID-19 and detection of viral RNA in fecal specimens suggest that SARS-CoV-2 might cause enteric, in addition to respiratory, infection(3,4). Here we demonstrate active replication of SARS-CoV-2 in human intestinal organoids and isolation of infectious virus from the stool specimen of a patient with diarrheal COVID-19. Collectively, we established the first expandable organoid culture system of bat intestinal epithelium and present evidence that SARS-CoV-2 can infect bat intestinal cells. The robust SARS-CoV-2 replication in human intestinal organoids suggests that the human intestinal tract might be a transmission route of SARS-CoV-2."],"journal":"Nat Med","authors":["Zhou, Jie","Li, Cun","Liu, Xiaojuan","Chiu, Man Chun","Zhao, Xiaoyu","Wang, Dong","Wei, Yuxuan","Lee, Andrew","Zhang, Anna Jinxia","Chu, Hin","Cai, Jian-Piao","Yip, Cyril Chik-Yan","Chan, Ivy Hau-Yee","Wong, Kenneth Kak-Yuen","Tsang, Owen Tak-Yin","Chan, Kwok-Hung","Chan, Jasper Fuk-Woo","To, Kelvin Kai-Wang","Chen, Honglin","Yuen, Kwok Yung"],"date":"2020-05-15T11:00:00Z","year":2020,"_id":"32405028","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1038/s41591-020-0912-6","locations":["Wuhan","China","horseshoe","Rhinolophus"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Mechanism","Transmission"],"weight":1,"_version_":1666950579830652928,"score":51.4718},{"pmid":32291076,"pmcid":"PMC7144854","title":"EZH2-mediated H3K27me3 inhibits ACE2 expression.","text":["EZH2-mediated H3K27me3 inhibits ACE2 expression.","The outbreak of corona virus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is spreading globally and quickly, leading to emerging health issues. SARS-CoV-2 enters into and infects host cells through its spike glycoprotein recognizing the cell receptor Angiotensin-converting enzyme II (ACE2). Here, we noticed that ACE2 was further enhanced by SARS-CoV-2 infection. Human germ cells and early embryos express high level of ACE2. Notably, RNA-seq result showed that reduction of H3K27me3, but not H3K4/9/36me3, led to upregulation of Ace2 expression in mouse germ cell line GC-2. In agreement with this result, we found in human embryonic stem cells that ACE2 expression was significantly increased in absence of EZH2, the major enzyme catalyzing H3K27me3. ChIP-seq analysis further confirmed decrease of H3K27me3 signal and increase of H3K27ac signal at ACE2 promoter upon EZH2 knockout. Therefore, we propose that EZH2-mediated H3K27me3 at ACE2 promoter region inhibits ACE2 expression in mammalian cells. This regulatory pattern may also exist in other human cells and tissues. Our discovery provides clues for pathogenesis and targeted drug therapy towards ACE2 expression for prevention and adjuvant therapy of COVID-19.","Biochem Biophys Res Commun","Li, Yuanyuan","Li, Honggang","Zhou, Liquan","32291076"],"abstract":["The outbreak of corona virus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is spreading globally and quickly, leading to emerging health issues. SARS-CoV-2 enters into and infects host cells through its spike glycoprotein recognizing the cell receptor Angiotensin-converting enzyme II (ACE2). Here, we noticed that ACE2 was further enhanced by SARS-CoV-2 infection. Human germ cells and early embryos express high level of ACE2. Notably, RNA-seq result showed that reduction of H3K27me3, but not H3K4/9/36me3, led to upregulation of Ace2 expression in mouse germ cell line GC-2. In agreement with this result, we found in human embryonic stem cells that ACE2 expression was significantly increased in absence of EZH2, the major enzyme catalyzing H3K27me3. ChIP-seq analysis further confirmed decrease of H3K27me3 signal and increase of H3K27ac signal at ACE2 promoter upon EZH2 knockout. Therefore, we propose that EZH2-mediated H3K27me3 at ACE2 promoter region inhibits ACE2 expression in mammalian cells. This regulatory pattern may also exist in other human cells and tissues. Our discovery provides clues for pathogenesis and targeted drug therapy towards ACE2 expression for prevention and adjuvant therapy of COVID-19."],"journal":"Biochem Biophys Res Commun","authors":["Li, Yuanyuan","Li, Honggang","Zhou, Liquan"],"date":"2020-04-16T11:00:00Z","year":2020,"_id":"32291076","source":"PubMed","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.bbrc.2020.04.010","keywords":["ace2","coronavirus","ezh2","h3.3","sars-cov-2"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494425104384,"score":48.099556},{"pmid":32311451,"pmcid":"PMC7165079","title":"Specific ACE2 Expression in Small Intestinal Enterocytes may Cause Gastrointestinal Symptoms and Injury after 2019-nCoV Infection.","text":["Specific ACE2 Expression in Small Intestinal Enterocytes may Cause Gastrointestinal Symptoms and Injury after 2019-nCoV Infection.","The coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China and rapidly spread in other countries in December 2019. The infected patients presented with fever, respiratory symptoms, sometimes with digestive and other systemic manifestations, and some progressed with a severe acute respiratory syndrome or even death. Associated digestive symptoms were frequently observed in the patients, with an unknown significance and mechanism. ACE2, as the major known functional receptor of the 2019 novel coronavirus (2019-nCoV) attracted our attention. We collected the clinical data of the 2019-nCoV-infected patients from published studies and extracted the data about the incidence of gastrointestinal symptoms. Furthermore, we used online datasets to analyze ACE2 expression in different human organs, especially in the small intestine, to explore the relationship between ACE2 expression patterns and clinical symptoms. We found that diarrhea accounted for a notable proportion of COVID-19 patients, ranging from 8.0% to 12.9%. The results reveal that ACE2 mRNA and protein are highly expressed in the small intestinal enterocytes but not in the goblet cells or intestinal immune cells. High expression of ACE2 on the surface cells in the digestive tract may lead to gastrointestinal symptoms and inflammation susceptibility. Overall, digestive symptoms were common in the COVID-19 patients. ACE2 expression on surface cells of the small intestine may mediate the invasion and amplification of the virus and activation of gastrointestinal inflammation. It is a possible mechanism of digestive symptoms in the COVID-19 patients and explains the presence of the virus in patients' stool samples. The study also highlights the necessity of taking stool samples for suspected patients to help in early diagnosis and assessment of disease status.","Int J Infect Dis","Zhang, Hui","Li, Hong-Bao","Lyu, Jian-Rui","Lei, Xiao-Ming","Li, Wei","Wu, Gang","Lyu, Jun","Dai, Zhi-Ming","32311451"],"abstract":["The coronavirus disease 2019 (COVID-19) was first reported in Wuhan, China and rapidly spread in other countries in December 2019. The infected patients presented with fever, respiratory symptoms, sometimes with digestive and other systemic manifestations, and some progressed with a severe acute respiratory syndrome or even death. Associated digestive symptoms were frequently observed in the patients, with an unknown significance and mechanism. ACE2, as the major known functional receptor of the 2019 novel coronavirus (2019-nCoV) attracted our attention. We collected the clinical data of the 2019-nCoV-infected patients from published studies and extracted the data about the incidence of gastrointestinal symptoms. Furthermore, we used online datasets to analyze ACE2 expression in different human organs, especially in the small intestine, to explore the relationship between ACE2 expression patterns and clinical symptoms. We found that diarrhea accounted for a notable proportion of COVID-19 patients, ranging from 8.0% to 12.9%. The results reveal that ACE2 mRNA and protein are highly expressed in the small intestinal enterocytes but not in the goblet cells or intestinal immune cells. High expression of ACE2 on the surface cells in the digestive tract may lead to gastrointestinal symptoms and inflammation susceptibility. Overall, digestive symptoms were common in the COVID-19 patients. ACE2 expression on surface cells of the small intestine may mediate the invasion and amplification of the virus and activation of gastrointestinal inflammation. It is a possible mechanism of digestive symptoms in the COVID-19 patients and explains the presence of the virus in patients' stool samples. The study also highlights the necessity of taking stool samples for suspected patients to help in early diagnosis and assessment of disease status."],"journal":"Int J Infect Dis","authors":["Zhang, Hui","Li, Hong-Bao","Lyu, Jian-Rui","Lei, Xiao-Ming","Li, Wei","Wu, Gang","Lyu, Jun","Dai, Zhi-Ming"],"date":"2020-04-21T11:00:00Z","year":2020,"_id":"32311451","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.ijid.2020.04.027","keywords":["2019-ncov","ace2","covid-19","diarrhea","small intestine"],"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138491173470209,"score":46.248867}]}